Yamile Lopez-Hernandez1,2, Jorge Alejandro Saldivar-Nava1, Idalia Garza-Veloz1,3,4, Ivan Delgado-Enciso5,6, Laura Elia Martinez-de-Villarreal7, Patricia Yahuaca-Mendoza1, Iram Pablo Rodriguez-Sanchez7, Laura Lopez-Gilibets1, Jorge Issac Galvan-Tejada3,4, Carlos Eric Galvan-Tejada3,4, Jose Maria Celaya-Padilla3,4, Margarita L Martinez-Fierro8,9,10. 1. Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Carretera Zacatecas-Guadalajara Km 6 Ejido la Escondida, Zacatecas, CP 98160, Mexico. 2. Catedras Program, Consejo Nacional de Ciencia y Tecnología (CONACYT), Ciudad de Mexico, Mexico. 3. Bioengineering Laboratory, Centro de Investigacion e Innovacion Tecnologica Industrial, Unidad Academica de Ingenieria Electrica, Universidad Autonoma de Zacatecas, Zacatecas, Mexico. 4. Grupo de Investigacion Regional Emergente (GIRE), Zacatecas, Mexico. 5. Facultad de Medicina, Universidad Autonoma de Colima, Colima, Mexico. 6. Servicios de Salud del Estado de Colima, Instituto Estatal de Cancerologia, Colima, Mexico. 7. Departamento de Genetica, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico. 8. Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas, Carretera Zacatecas-Guadalajara Km 6 Ejido la Escondida, Zacatecas, CP 98160, Mexico. margaritamf@uaz.edu.mx. 9. Bioengineering Laboratory, Centro de Investigacion e Innovacion Tecnologica Industrial, Unidad Academica de Ingenieria Electrica, Universidad Autonoma de Zacatecas, Zacatecas, Mexico. margaritamf@uaz.edu.mx. 10. Grupo de Investigacion Regional Emergente (GIRE), Zacatecas, Mexico. margaritamf@uaz.edu.mx.
Abstract
PURPOSE: The aim of this study was to evaluate the usefulness of urine concentrations of 12 proteins as a risk parameter for developing preeclampsia (PE). METHODS: A nested case-control study was designed to determine protein concentrations in urine from women predicted to develop PE (WPD-PE) and normotensive pregnancies (controls). Protein profiles were determined at 12, 16 and 20 gestational weeks (GW) using the Bio-Plex Pro human kidney toxicity Panel 1 and Panel 2 (Bio-Rad). Receiver operating characteristic (ROC) curve analyses were performed. Correlations between proteins and clinical parameters at the time of PE diagnosis were also assessed. RESULTS: Significant differences were observed in urine cystatin C (Cys C) levels at 16 and 20 GW and clusterin at 20 GW between WPD-PE and controls (P < 0.05). ROC analysis revealed that Cys C at 16 GW had the highest area under the ROC curve (0.758). At 16 GW, patients with urine Cys C levels above 73.7 ng/mL had eightfold increased odds for developing PE (odds ratio 7.92; 95 % CI 1.3-47.5; P = 0.027). A positive correlation was found between urinary Cys C (at 16 and 20 GW) and leukocyte counts, total proteins, aspartate aminotransferase, alanine aminotransferase, bilirubin and lactate dehydrogenase at the time of PE diagnosis (P value < 0.05). CONCLUSIONS: Urinary Cys C and clusterin showed predictive value for PE development in our cohort. Further studies are needed to validate their use as predictive biomarkers for PE and/or their participation in PE pathogenesis.
PURPOSE: The aim of this study was to evaluate the usefulness of urine concentrations of 12 proteins as a risk parameter for developing preeclampsia (PE). METHODS: A nested case-control study was designed to determine protein concentrations in urine from women predicted to develop PE (WPD-PE) and normotensive pregnancies (controls). Protein profiles were determined at 12, 16 and 20 gestational weeks (GW) using the Bio-Plex Pro humankidney toxicity Panel 1 and Panel 2 (Bio-Rad). Receiver operating characteristic (ROC) curve analyses were performed. Correlations between proteins and clinical parameters at the time of PE diagnosis were also assessed. RESULTS: Significant differences were observed in urine cystatin C (Cys C) levels at 16 and 20 GW and clusterin at 20 GW between WPD-PE and controls (P < 0.05). ROC analysis revealed that Cys C at 16 GW had the highest area under the ROC curve (0.758). At 16 GW, patients with urine Cys C levels above 73.7 ng/mL had eightfold increased odds for developing PE (odds ratio 7.92; 95 % CI 1.3-47.5; P = 0.027). A positive correlation was found between urinary Cys C (at 16 and 20 GW) and leukocyte counts, total proteins, aspartate aminotransferase, alanine aminotransferase, bilirubin and lactate dehydrogenase at the time of PE diagnosis (P value < 0.05). CONCLUSIONS: Urinary Cys C and clusterin showed predictive value for PE development in our cohort. Further studies are needed to validate their use as predictive biomarkers for PE and/or their participation in PE pathogenesis.
Authors: Stefan Verlohren; Nele Geusens; Jude Morton; Iris Verhaegen; Lydia Hering; Florian Herse; Joachim W Dudenhausen; Dominik N Muller; Friedrich C Luft; Judith E Cartwright; Sandra T Davidge; Robert Pijnenborg; Ralf Dechend Journal: Hypertension Date: 2010-07-06 Impact factor: 10.190
Authors: Lissette C Sánchez-Aranguren; Carlos E Prada; Carlos E Riaño-Medina; Marcos Lopez Journal: Front Physiol Date: 2014-10-10 Impact factor: 4.566
Authors: Gunnar Schley; Carmen Köberle; Ekaterina Manuilova; Sandra Rutz; Christian Forster; Michael Weyand; Ivan Formentini; Rosemarie Kientsch-Engel; Kai-Uwe Eckardt; Carsten Willam Journal: PLoS One Date: 2015-12-15 Impact factor: 3.240
Authors: Fernanda Regina Giachini; Carlos Galaviz-Hernandez; Alicia E Damiano; Marta Viana; Angela Cadavid; Patricia Asturizaga; Enrique Teran; Sonia Clapes; Martin Alcala; Julio Bueno; María Calderón-Domínguez; María P Ramos; Victor Vitorino Lima; Martha Sosa-Macias; Nora Martinez; James M Roberts; Carlos Escudero Journal: Curr Hypertens Rep Date: 2017-10-06 Impact factor: 5.369
Authors: Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe Journal: JCI Insight Date: 2018-10-04